Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride Treatment of biliary tract cancer, 10/11/2022 Positive
Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride Treatment of biliary tract cancer, 10/11/2022 Positive
![Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride Treatment of biliary tract cancer, 10/11/2022 Positive](https://www.ema.europa.eu/sites/default/files/styles/oe_bootstrap_theme_medium_no_crop/public/2024-07/EMA_building_202407_v1-copyright-EMA.png?itok=NBYia_Eu)
Orphan designation: N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride Treatment of biliary tract cancer, 10/11/2022 Positive
